Projects per year
Abstract
AIM: To investigate glucose and insulin metabolism in participants with ataxia telangiectasia in the absence of a diagnosis of diabetes.
METHODS: A standard oral glucose tolerance test was performed in participants with ataxia telangiectasia (n=10) and in a control cohort (n=10). Serial glucose and insulin measurements were taken to permit cohort comparisons of glucose-insulin homeostasis and indices of insulin secretion and sensitivity.
RESULTS: During the oral glucose tolerance test, the 2-h glucose (6.75 vs 4.93 mmol/l; P=0.029), insulin concentrations (285.6 vs 148.5 pmol/l; P=0.043), incremental area under the curve for glucose (314 vs 161 mmol/l/min; P=0.036) and incremental area under the curve for insulin (37,720 vs 18,080 pmol/l/min; P =0.03) were higher in participants with ataxia telangiectasia than in the controls. There were no significant differences between groups in fasting glucose, insulin concentrations or insulinogenic index measurement (0.94 vs 0.95; P=0.95). The Matsuda index, reflecting whole-body insulin sensitivity, was lower in participants with ataxia telangiectasia (5.96 vs 11.03; P=0.019) than in control subjects.
CONCLUSIONS: Mutations in Ataxia Telangiectasia Mutated (ATM) that cause ataxia telangiectasia are associated with elevated glycaemia and low insulin sensitivity in participants without diabetes. This indicates a role of ATM in glucose and insulin metabolic pathways. This article is protected by copyright. All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 371-375 |
Number of pages | 5 |
Journal | Diabetic Medicine |
Volume | 33 |
Issue number | 3 |
Early online date | 24 Dec 2015 |
DOIs | |
Publication status | Published - Mar 2016 |
Fingerprint
Dive into the research topics of 'Recessive mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance'. Together they form a unique fingerprint.Projects
- 1 Finished
-
Stratified Medicine in Type 2 Diabetes: Insights from the Study of Drug Response (New Investigator Award)
Pearson, E. (Investigator)
16/02/15 → 15/08/21
Project: Research